Nestlé Health Science completes investment in Seres Health Dienstag, 06. Januar 2015 - 15:10

Nestlé Health Science completes investment in Seres Health

Nestlé Health Science has completed a CHF65.6 million investment in Seres Health Inc.

Seres Health Inc., based in Cambridge, Massachusetts, USA, is a leading microbiome therapeutics company that is developing a novel class of biological drugs designed to treat diseases by restoring the function of the microbiome. The microbiome consists of around 100 trillion microorganisms that live in the body and perform a variety of functions, including supporting the immune system.

Read the full announcement: www.nestlehealthscience.com/newsroom/press-releases/Investment-in-Microbiome-Therapeutics-Leader-Seres-Health-and-Strategic-Innovation-Partnership-with-Flagship-Ventures

More stories on our Nestlé News Feed: www.nestle.com/media

Media enquiries
Nestlé S.A. Vevey, Switzerland
Tel: +41 21 924 2200
Email: mediarelations@nestle.com

Follow Nestlé news
Twitter | Flickr | Facebook | YouTube